NASDAQ:ASBP Aspire Biopharma (ASBP) Stock Price, News & Analysis $7.89 -0.41 (-4.94%) Closing price 11/18/2026 03:59 PM EasternExtended Trading$8.12 +0.23 (+2.97%) As of 11/18/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Aspire Biopharma Stock (NASDAQ:ASBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aspire Biopharma alerts:Sign Up Key Stats Today's Range$7.89▼$8.7050-Day Range$6.76▼$9.1252-Week Range$3.31▼$205.20Volume7,986 shsAverage Volume21,719 shsMarket Capitalization$11.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Aspire Biopharma is a biopharmaceutical company developing drug products that use sublingual delivery, in which a medicine is placed under the tongue for absorption. Its platform is intended to create rapidly absorbed formulations of existing drugs. The company has highlighted sublingual formulations based on aspirin and caffeine among its product candidates. These are under development; Aspire’s focus is on developing potential therapies rather than marketing an established portfolio of approved products.AI Generated. May Contain Errors. Read More Aspire Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreASBP MarketRank™: 0.85 of 5 starsAspire Biopharma scored higher than 17% of companies evaluated by MarketBeat, and ranked 887th out of 938 stocks in the consumer discretionary sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAspire Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAspire Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Aspire Biopharma's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.45% of the float of Aspire Biopharma has been sold short.Short Interest Ratio / Days to CoverAspire Biopharma has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aspire Biopharma has recently decreased by 32.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAspire Biopharma does not currently pay a dividend.Dividend GrowthAspire Biopharma does not have a long track record of dividend growth. News and Social Media0.8 / 5News SentimentN/A News SentimentAspire Biopharma has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Consumer Discretionary companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aspire Biopharma this week, compared to 2 articles on an average week. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aspire Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of Aspire Biopharma is held by insiders.Percentage Held by Institutions19.17% of the stock of Aspire Biopharma is held by institutions.Read more about Aspire Biopharma's insider trading history. Receive ASBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aspire Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASBP Stock News HeadlinesAspire Biopharma Reports Delay in Quarterly FilingNovember 16 at 7:51 PM | tipranks.comAspire-Lakewood Launches $10 Million Share Repurchase ProgramSeptember 9, 2026 | tipranks.comYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills. | Profits Run (Ad)Aspire Biopharma Holdings, Inc.: Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase ProgramSeptember 9, 2026 | finanznachrichten.deAspire Biopharma Changes Name to Aspire-Lakewood Holdings Inc.September 8, 2026 | usatoday.comAspire Biopharma Renamed Aspire-Lakewood Holdings, Inc.September 8, 2026 | tipranks.comAspire Biopharma Holdings Inc ASBPAugust 18, 2026 | morningstar.comMAspire Biopharma Holdings, Inc.: Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMBJuly 21, 2026 | finanznachrichten.deSee More Headlines ASBP Stock Analysis - Frequently Asked Questions How have ASBP shares performed this year? Aspire Biopharma's stock was trading at $158.28 at the beginning of the year. Since then, ASBP stock has decreased by 95.0% and is now trading at $7.89. How were Aspire Biopharma's earnings last quarter? Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) issued its earnings results on Friday, November, 14th. The company reported ($48.00) EPS for the quarter. The firm had revenue of $1.94 thousand for the quarter. When did Aspire Biopharma's stock split? Aspire Biopharma shares reverse split before market open on Monday, May 11th 2026.The 1-30 reverse split was announced on Thursday, May 7th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Aspire Biopharma? Shares of ASBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Automobile Components Sub-IndustryAutomotive Parts & Equipment Current SymbolNASDAQ:ASBP Previous SymbolNASDAQ:PWUP CIK1847345 Webaspirebiolabs.com Phone(561) 704-8527FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($69.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.48 million Net Margins-11,362.21% Pretax Margin-11,361.18% Return on EquityN/A Return on Assets-177.59% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.82 Sales & Book Value Annual Sales$10 thousand Price / Sales1,104.60 Cash FlowN/A Price / Cash FlowN/A Book Value($54.19) per share Price / Book-0.15Miscellaneous Outstanding Shares1,400,000Free Float1,322,000Market Cap$11.05 million OptionableN/A Beta0.17 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:ASBP) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aspire Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aspire Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.